Fundraising Foximbiologics
4 known investors
Find your way into imbiologics
Sign up to find every way you can get introduced to imbiologics
- Your email: who you already know at imbiologics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the imbiologics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
The page is a stock price information page (share price, trading volume, and market cap history) rather than a descriptive company page, so it provides no usable detail about what the company does.
Also known as ImBiologics · IMBiologics Corp. · 아이엠바이오 · 아이엠바이오로직스
Investors · 4
Company profile
researched Aug 2026ImBiologics (아이엠바이오로직스) is a South Korea-based biotechnology company specializing in the discovery and development of innovative antibody therapeutics. Established in August 2020, the company builds its pipeline around immunomodulatory biologics, targeting autoimmune diseases and immuno-oncology indications where it states existing therapies leave unmet medical need.
The company's work centers on an in-house antibody modality design and optimization platform, referred to as IM-OpDECon, which it uses to construct and optimize antibody formats across antigen binding, antibody function and biophysical properties. Named programs referenced on the company's site include IMB-101 and IMB-106. The company describes an ambition to grow into a biotech capable of independently developing and obtaining approval for novel drugs, positioning itself in immune-mediated disease.
Business model
The company develops antibody drug candidates in-house and pursues partnering and licensing-out of programs with global partners, alongside investor relations activity indicating external capital raising.
Traction
Company communications reference clinical attention for IMB-101, preclinical-stage progress and licensing-out expectations for IMB-106, and expectations that clinical results in 2027 would be a value inflection point.
Latest developments
In mid-2026, company press coverage highlighted a global strategy centered on IMB-106 with expectations spanning preclinical work through licensing-out, business development discussions for next-generation pipeline assets at BIO USA, attention on the IMB-101 clinical program and follow-on licensing prospects, and commentary that 2027 clinical results would be a catalyst for the company's valuation.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company positions its differentiation in the ability to design and optimize varied antibody modalities via IM-OpDECon in order to address indications in autoimmune disease and immuno-oncology that it says are not resolved by existing therapies.
Technology
ImBiologics' core technology is IM-OpDECon, described as an optimal antibody modality construction technology. It is applied to expand the pipeline by optimizing antigen binding, antibody function and antibody developability/physical properties, and supports the use of multiple antibody modalities.
Go-to-market
The company pursues business development with global partners, including out-licensing discussions and participation in industry conferences such as BIO USA, where it discussed commercialization of next-generation pipeline assets.
Geography
Headquartered in South Korea, with business development activity aimed at global partners and participation in international industry events.
History
ImBiologics was founded in August 2020 as a company dedicated to developing innovative antibody drugs, operating under the slogan "Innovative Medicines based on ImmunoModulatory Biologics."
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsPress release referenced on the company's site describing a global push centered on the IMB-106 program with expectations spanning preclinical development and licensing-out.
The company reported beginning commercialization discussions for its next-generation pipeline at the BIO USA convention.
Press item noting focus on the IMB-101 clinical program, with follow-on licensing-out cited as a key variable.
Press item stating that clinical results expected in 2027 would be a momentum driver for the company's value.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 2
primary sources listed
- imbiologics Venture Capitalimbiologics.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does imbiologics do?
- Korean biotech developing immunomodulatory antibody therapeutics for autoimmune disease and immuno-oncology.
- Who are imbiologics's investors?
- imbiologics's investors include Aju IB Invesment Corporation, Atinum Investment Co. Ltd., IMM Investment Japan, Solidus Investment.